Gonorrhea Therapeutics Market: By Gonococcal Infection (Uncomplicated Gonococcal Infection, Gonococcal Arthritis, Gonococcal Meningitis, and Endocarditis), By Treatment (Monotherapy, Dual Therapy), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Gonorrhea Therapeutics Market was valued at USD 1,365.3 million in 2023 and is expected to grow at an 4.6% CAGR from 2024-2030. Gonorrhea is a common sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It is also known as ‘the clap’ or ‘drip’. Gonorrhea is the second-most commonly reported notifiable disease. The increasing incidence of Neisseria gonorrhoeae infections contributes to the demand for effective treatments. The factors that are driving this market are the growing burden of gonorrhea and growing government and private sector participation through national campaigns. Moreover, the COVID-19 pandemic also impacted the gonorrhea therapeutics market majorly. The increased number of gonorrhea cases worldwide is leading to a demand for better therapeutics, thereby driving the demand for gonorrhea therapeutics. Most cases were in the African Region and the Western Pacific Region. Thus, increasing gonorrhea cases are increasing the demand for gonorrhea therapeutics and thus driving the demand for this market. Ongoing research focuses on novel drugs and therapies.

Antimicrobial peptides, vaccines, and combination therapies offer promising avenues for improved treatment outcomes. Moreover, the growing government and private sector participation in national campaigns is also fueling the growth of the studied market. For instance, in August 2022, WHO reported that the Global Health Sector Strategy on HIV, Hepatitis, and STIs (2022-2030) has set targets to reduce the number of new cases of gonorrhea among people 15-49 years old from 82.3 million per year in 2020 to 8.23 million per year in 2030, thus reducing the annual incidence by 90% by 2030. The effective prevention and control of gonococcal infections by using prevention messages, interventions, and the right treatment plans. However, gonorrhea’s ability to develop resistance poses a significant challenge. Overcoming resistance requires innovative approaches and new therapeutic options. Moreover, financial constraints hinder the therapeutic advancements. Dual therapy (combining two drugs) enhances treatment efficacy and addresses resistance. Researchers explore synergistic approaches to combat gonorrhea. Advanced diagnostics and personalized medicine contribute to precise treatment strategies. Targeted therapies improve patient outcomes.

Gonorrhea Therapeutics Marke Recent Market Developments:
  • In August 2022, Scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) developed a new preclinical drug, JSF-2659, for eradicating the bacteria causing gonorrhea.

Gonorrhea Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.6%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Gonorrhea Therapeutics Market Dynamics

The COVID-19 pandemic impacted routine sexually transmitted infection services, suggesting an increase in syndromic sexually transmitted infections and missing asymptomatic cases. The pandemic also had a major impact on the gonorrhea therapeutics market. For instance, according to a research study2022, testing and treatment algorithms for sexually transmitted diseases (STDs) like gonorrhea were impacted during the pandemic due to a decrease in staffing coupled with reduced diagnostic capability and disturbances in the supply chain that led to a decrease or delay in gonorrhea diagnosis and treatment that led to an increase in gonorrhea. Thus, the COVID-19 pandemic impacted the gonorrhea therapeutics market. However, in the current scenario, with the decrease in COVID-19 cases and the resumption of healthcare services, the market is expected to witness significant growth over the forecast period. The other factors that are driving this market are the growing burden of gonorrhea and growing government and private sector participation through national campaigns. The increased number of gonorrhea cases worldwide is leading to a demand for better therapeutics, thereby driving the demand for gonorrhea therapeutics.

Gonorrhea Therapeutics Market Segmentation

By Gonococcal Infection
  • Uncomplicated Gonococcal Infection
  • Gonococcal Arthritis
  • Gonococcal Meningitis and Endocarditis
By Treatment
  • Monotherapy
  • Dual Therapy
By Route of Administration
  • Oral
  • Injectable
By End User
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

Gonorrhea Therapeutics Market was valued at USD 1,365.3 million in 2023 and is expected to grow at an 4.6% CAGR from 2024 to 2030.

AbbVie (Allergan, Inc.), F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, and Pfizer Inc. are some of the major players operating in the gonorrhea therapeutics market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period.

North America accounts for the largest market share and is expected to be the primary market driver in the gonorrhea therapeutics market.

Gonorrhea’s ability to develop resistance poses a significant challenge. Moreover, financial constraints hindering therapeutic advancements are expected to limit the growth of the gonorrhea therapeutics market.

Key Features of the Reports

  • The gonorrhea therapeutics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
1.Executive Summary
2.Global Gonorrhea Therapeutics Market Introduction 
2.1.Global Gonorrhea Therapeutics Market  - Taxonomy
2.2.Global Gonorrhea Therapeutics Market  - Definitions
2.2.1.Gonococcal Infection
2.2.2.Treatment
2.2.3.Route of Administration
2.2.4.End User
2.2.5.Region
3.Global Gonorrhea Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Gonorrhea Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Gonorrhea Therapeutics Market  By Gonococcal Infection, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Uncomplicated Gonococcal Infection
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Gonococcal Arthritis
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Gonococcal Meningitis and Endocarditis
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Gonorrhea Therapeutics Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Monotherapy
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Dual Therapy
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Gonorrhea Therapeutics Market  By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Injectable
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Gonorrhea Therapeutics Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Others
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Gonorrhea Therapeutics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Gonococcal Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Uncomplicated Gonococcal Infection
10.1.2.Gonococcal Arthritis
10.1.3.Gonococcal Meningitis and Endocarditis
10.2.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Monotherapy
10.2.2.Dual Therapy
10.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Injectable
10.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.4.4.Others
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Gonococcal Infection Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Uncomplicated Gonococcal Infection
11.1.2.Gonococcal Arthritis
11.1.3.Gonococcal Meningitis and Endocarditis
11.2.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Monotherapy
11.2.2.Dual Therapy
11.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Injectable
11.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.4.4.Others
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Gonococcal Infection Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Uncomplicated Gonococcal Infection
12.1.2.Gonococcal Arthritis
12.1.3.Gonococcal Meningitis and Endocarditis
12.2.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Monotherapy
12.2.2.Dual Therapy
12.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Injectable
12.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.4.4.Others
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Gonococcal Infection Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Uncomplicated Gonococcal Infection
13.1.2.Gonococcal Arthritis
13.1.3.Gonococcal Meningitis and Endocarditis
13.2.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Monotherapy
13.2.2.Dual Therapy
13.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Injectable
13.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.4.4.Others
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Gonococcal Infection Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Uncomplicated Gonococcal Infection
14.1.2.Gonococcal Arthritis
14.1.3.Gonococcal Meningitis and Endocarditis
14.2.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Monotherapy
14.2.2.Dual Therapy
14.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Injectable
14.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.4.4.Others
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.AbbVie
15.2.2.Allergan, Inc.
15.2.3.Hoffmann-La Roche Ltd
15.2.4.GlaxoSmithKline plc
15.2.5.Lupin Pharmaceuticals
15.2.6.Pfizer Inc.
15.2.7.Teligent, Inc.
15.2.8.Merck & Co., Inc.
15.2.9.Hologic, Inc.
15.2.10.Danaher Corporation
15.2.11.Abbott
15.2.12.Becton Dickinson and Company
16. Research Methodology 
17. Appendix and Abbreviations 
  • AbbVie
  • Allergan, Inc.
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals
  • Pfizer Inc.
  • Teligent, Inc.
  • Merck & Co., Inc.
  • Hologic, Inc.
  • Danaher Corporation
  • Abbott
  • Becton Dickinson and Company

Adjacent Markets